Flightpath Biosciences

Executive Summary

Flightpath Biosciences is a San Diego-based biotechnology company founded in 2020, pioneering a novel Targeted Bacterial Deletion™ platform to selectively eliminate pathogenic gram-negative bacteria while preserving the healthy microbiome. The company targets complex diseases driven by bacterial infections across oncology, oral health, gastrointestinal disorders, and women's health. By precisely removing root-cause pathogens, Flightpath aims to address unmet needs in anti-infective therapy, particularly in indications where traditional antibiotics disrupt the microbiome or drive resistance. The platform's ability to spare beneficial bacteria positions it as a potential paradigm shift in treating microbiome-associated diseases. While the company is still in early development stages with no disclosed pipeline details, its innovative approach and broad applicability across multiple therapeutic areas make it an intriguing prospect in precision anti-infectives. The management team's focus on gram-negative pathogens, which are often harder to treat, underscores the platform's potential impact. Flightpath's progress will depend on advancing lead candidates into preclinical studies and securing partnerships or funding to support IND-enabling activities.

Upcoming Catalysts (preview)

• Q4 2026Series A or Seed Extension Funding Round70% success
• H1 2027Lead Program Preclinical Proof-of-Concept Data50% success
• Q2 2027Academic or Industry Partnership for Platform Validation40% success